Molecular Oncology
Volume 3, Issue 5 , Pages 469-482 , December 2009

Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models

  • Anna Bergamaschi

      Affiliations

    • Department of Genetics, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • ,
  • Geir Olav Hjortland

      Affiliations

    • Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • ,
  • Tiziana Triulzi

      Affiliations

    • Department of Experimental Oncology, National Cancer Institute, Milan, Italy
    • ,
  • Therese Sørlie

      Affiliations

    • Department of Genetics, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Department of Informatics, University of Oslo, Norway
    • ,
  • Hilde Johnsen

      Affiliations

    • Department of Genetics, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • ,
  • Anne Hansen Ree

      Affiliations

    • Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Akershus University Hospital, Lorenskog, Norway
    • ,
  • Hege Giercksky Russnes

      Affiliations

    • Department of Genetics, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • ,
  • Sigurd Tronnes

      Affiliations

    • Akershus University Hospital, Lorenskog, Norway
    • ,
  • Gunhild M. Mælandsmo

      Affiliations

    • Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • ,
  • Oystein Fodstad

      Affiliations

    • Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Faculty Division, The Norwegian Radium Hospital, Faculty of Medicine, University of Oslo, Norway
    • ,
  • Anne-Lise Borresen-Dale

      Affiliations

    • Department of Genetics, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Faculty Division, The Norwegian Radium Hospital, Faculty of Medicine, University of Oslo, Norway
    • ,
  • Olav Engebraaten

      Affiliations

    • Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway
    • Faculty Division, The Norwegian Radium Hospital, Faculty of Medicine, University of Oslo, Norway
    • Corresponding Author InformationCorresponding author at: Department of Tumor Biology, Norwegian Radium Hospital, Ullernchausseen 70, Montebello, N-0310 Oslo, Norway.

Received 22 May 2009 ,Revised 18 July 2009 ,Accepted 21 July 2009.

References 

  1. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer. 2006;45(11):1033–1040
  2. Bergamaschi A, Tagliabue E, Sorlie T, Naume B, Triulzi T, Orlandi R, et al Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J. Pathol. 2008;214(3):357–367
  3. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015):332–337
  4. Church GM, Gilbert W. Genomic sequencing. Proc. Natl. Acad. Sci. U.S.A. 1984;81(7):1991–1995
  5. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol. 2006;17(5):818–826
  6. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001;61(6):2505–2512
  7. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, et al HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 2007;357(15):1496–1506
  8. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, et al Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69(10):4116–4124
  9. Lingjaerde OC, Baumbusch LO, Liestol K, Glad IK, Borresen-Dale AL. CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics. 2005;21(6):821–822
  10. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408
  11. Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, et al. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res. 2009;69(2):466–474
  12. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res. 2007;13(13):3989–3998
  13. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin. Cancer Res. 2007;13(7):1950–1954
  14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005;353(16):1659–1672
  15. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology. 2009;41(1):40–47
  16. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005;353(16):1673–1684
  17. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al. Triple-negative breast cancer: risk factors to potential targets. Clin. Cancer Res. 2008;14(24):8010–8018
  18. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127
  19. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 2003;100(14):8418–8423
  20. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001;98(19):10869–10874
  21. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 2005;102(43):15545–15550
  22. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A. 2001;98(9):5116–5121
  23. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, et al Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J. Clin. Oncol. 2004;22(11):2061–2068

PII: S1574-7891(09)00102-1

doi: 10.1016/j.molonc.2009.07.003

Molecular Oncology
Volume 3, Issue 5 , Pages 469-482 , December 2009

Article Tools

* Image Usage & Resolution